Skip to content

Intravenous Tramadol and Magnesium Sulphate for Prevention of Shivering

Comparative Study Between Intravenous Tramadol and Magnesium Sulphate for Prevention of Shivering Post Intrathecal Anesthesia a Randomized Clinical Study

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06612996
Enrollment
180
Registered
2024-09-25
Start date
2024-10-10
Completion date
2025-01-10
Last updated
2024-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hernia, Lower Extremity Chronic Venous Ulcers, Varicose Veins Leg

Keywords

Tramadol, Magnesium Sulphate, Shivering

Brief summary

The aim of this work was to compare the efficacy of intravenous (IV) tramadol versus magnesium sulphate added to 100 ml saline for prevention of shivering associated with spinal anesthesia.

Interventions

DRUGTramadol

Intravenous tramadol

DRUGMagnesium sulphate

Intravenous magnesium sulphate

OTHERSaline

Normal saline

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

\- American Society of Anesthesiologists (ASA) I and II physical status undergoing an elective surgery under spinal anesthesia.

Exclusion criteria

* history of uncontrolled comorbidities, cardiac, respiratory, renal or hepatic disease, patients who had allergy to any medication in the study, contraindications to spinal anesthesia (coagulation disorder, infection at site of puncture, raised intracranial tension or any spine deformity), fever >38 Celsius or less than 36 Celsius, body mass index more than 35 and who has history of alcohol intake

Design outcomes

Primary

MeasureTime frameDescription
Shivering score90 minutes postoperativelyShivering score

Contacts

Primary ContactWarda Demerdash Ali, PhD
warda2001@hotmail.com088 2148087

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026